Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group

RL Mulder, A Font-Gonzalez, MM Hudson, HM van Santen, EAH Loeffen, KC Burns, GP Quinn, E van Dulmen-Den Broeder, J Byrne, R Haupt, WH Wallace, Marry Van den Heuvel - Eibrink, A Anazodo, RA Anderson, A Barnbrock, JD Beck, AME Bos, I Demeestere, C Denzer, N di IorgiHR Hoefgen, R Kebudi, C Lambalk, T Langer, LR Meacham, K Rodriguez-Wallberg, C Stern, E Stutz-Grunder, Wendy Dorp, M Veening, S Veldkamp, E van der Meulen, LS Constine, LB Kenney, MDV de Wetering, LC Kremer, J Levine, WJ Tissing, C Berger, T Diesch, U Dirksen, J Ginsberg, A Giwercman, D Grabow, C Gracia, SE Hunter, J Inthorn, P Kaatsch, JF Kelvin, JL Klosky, Joop Laven, BA Lockart, S.J.C.M.M. Neggers, NW Paul, M Peate, B Phillips, DR Reed, EME Tinner, M Berg, C Verhaak

Research output: Contribution to journalArticleAcademic

30 Citations (Scopus)

Abstract

Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.

Original languageEnglish
Pages (from-to)e45-e56
JournalThe Lancet Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - 2021

Fingerprint

Dive into the research topics of 'Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group'. Together they form a unique fingerprint.

Cite this